SOUTH SAN FRANCISCO, Calif., Oct. 31 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on oncology, today announced that Jerry McMahon, Ph.D., chairman, president and CEO, will present at the Rodman & Renshaw 8th Annual Healthcare Conference on Monday, November 6, at 11:20 a.m. Eastern Time at the New York Palace Hotel.
Dr. McMahon will provide an update on the clinical development program for the Company's lead product candidate, picoplatin, a new generation platinum therapy that provides a differentiated spectrum of activity and an improved safety profile. Currently, picoplatin is being studied in an ongoing multi- center Phase 2 clinical trial in patients with small cell lung cancer and in Phase 1/2 clinical trials in patients with colorectal cancer and prostate cancer.
A live webcast of the presentation will be available on the "Events" page of the "News & Events" section of the Company's website at www.poniard.com. A replay will also be available for 10 days following the live presentation.
About Poniard Pharmaceuticals
Poniard Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the discovery, development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead product candidate, is a new generation platinum therapy with an improved safety profile. An intravenous chemotherapeutic agent, it is designed to overcome platinum resistance associated with the treatment of solid tumors. Picoplatin is currently being studied in clinical trials for the treatment of small cell lung, colorectal and hormone-refractory prostate cancers. Poniard has received orphan drug designation from the U.S. Food and Drug Administration for picoplatin for the treatment of small cell lung cancer. As part of the Company's strategic goal of building a diverse oncology pipeline, the Company also is collaborating with the Scripps Florida Research Institute on the discovery of novel, small-molecule, multi-targeted protein kinase inhibitors. For additional information please visit www.poniard.com.
NOTE: Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.
Poniard Pharmaceuticals, Inc.CONTACT: Julie Rathbun, Corporate Communications of PoniardPharmaceuticals, +1-206-286-2517, or jrathbun@poniard.com
Web site: http://www.poniard.com/
